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A Two-Year Study with Cimetidine in the Rat: Assessment for Chronic Toxicity and
Carcinogenicity. LESLIE, G. B., NOAKES, D. N., POLLITT, F. D., ROE, F. J. C., AND WALKER
T. F. (1981). Toxicol. Appl. PharmacoL 61, 119-137. Cimetidine [Am-cyano-N-methyl-N1-
{2- [(5-methylimidazol-4-yl)methylthio]ethyl}guanidine] was administered daily for 2 years
by gavage to Wistar rats at dose levels of 950, 378, and 150 mg/kg/day. Two groups, one
receiving distilled wathr daily and the other not treated, served as controls. Premature deaths
occurred when cimetidine was accidentally introduced into the lungs or reached the lungs by
seepage from the esophagus via the larynx during intragastric administration but cimetidine
treatment did not otherwise affect survival, body weight gain, clinical condition, and hema-
tological, or urinalysis parameters. Raised transaminase levels occurred occasionally during
the second year of the study in top dose males and there was a significant increase in mean
liver weight in top dose females killed terminally compared with controls. Histopathological
observations of the livers of these animals indicated only nonspecific changes. Mean prostate
and seminal vesicle weights were significantly lower in all groups receiving cimetidine than
in controls and there was dose-related atrophy of the seminiferous tubules and atrophy of the
male secondary sex organs. There were no other apparent effects of treatment on nontumor
pathology. Overall tumor incidence, after the exclusion of Leydig-cell tumors, was not affected
by cimetidine treatment. A significantly higher incidence of benign Leydig-cell tumors in the
combined cimetidine-treated groups compared with the combined control groups was confined
to rats killed during Weeks 105 and 106 and was not dose related. No meaningful treatment-
related effects on incidence were observed for any other kind of neoplasm.
Cimetidine is a specific, competitive hista-
mine H2-receptor antagonist as defined by
Black et al. (1972) and is an effective in-
hibitor of gastric acid secretion in animals
and in man. Cimetidine has been shown to
have low acute toxicity and repeated dose
studies of up to 12 months duration in rats
and dogs have revealed no major adverse
effects (Leslie and Walker, 1977). Weak
antiandrogenic effects, resulting in reduction
in weight of the secondary sex organs in
males, were observed in both rats and dogs
but a formal test in male rats showed that
potency and fertility were not affected. Ci-
metidine was not teratogenic in rabbits or
rats and did not affect the fertility of female
rats.
The present paper presents the results of
a 2-year toxicity study in the rat with par-
ticular attention to incidences of neoplastic
lesions.
METHODS
Compound. Cimetidine (N"-cyano-N-methyl-N'- {2-
[(5 - methylimidazol-4 - yOmethylthio]ethyllguanidine]
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was obtained from our own laboratories at Welwyn
Garden City and from Bridge Chemicals Ltd., Ton-
bridge. Five batches of cimetidine, all of clinical grade
purity, were used sequentially during the study. A molar
stock solution of cimetidine base was made up once
weekly by gentle heating with 1 N hydrochloric acid to
give a solution of pH 6-7. This was diluted daily with
distilled . water to give fresh dosing solutions.
Animals and environment. The rats were of an ICI
Wistar-derived strain, bred in our laboratories from
caesarian-derived, barrier-maintained stock, specified
pathogen-free, and inoculated with a known gut flora.
They were 51/2 weeks old when dosing commenced. The
rats were housed in groups of five in polypropylene cages
with stainless-steel grid tops and solid bases with white
woodchip bedding. Porton Rat Diet (Labsure Ltd.,
Poole, Dorset) and tap water were available ad lib.
Room temperature was maintained at 20°C ( ± 2°C)
with a relative humidity of 42% ( ± 8%). The room was
lit by fluorescent tubes, with a 12-hr, light-dark cycle.
Diet. The manufacturer's specifications for Porton
Rat Diet appear in Table 1.
Dosing procedure. Male (426) and female (427) rats
of four different batches (A-D) were allocated ran-







Distilled water by gavage
Nondosed controls
Further details of allocation of rats of different batches
to groups are shown in Table 2. As indicated in a foot-
note to that table the assessment of chronic toxicity was
based on observations made on Batches A and B only.
The doses of cimetidine were equivalent to 190, 75,
and 30 times those required for 50% inhibition of basal
gastric acid secretion in the rat, as previously estimated
in SK & F Laboratories. On a body weight basis these
doses are equivalent to 57, 22.6, and 9 times the rec-
ommended daily dose for a 60-kg human (1 g in U.K.),
respectively. For administration of cimetidine to rats at
those dose levels up to 950 mg/kg/day, gavage was con-
sidered preferable to administration in the diet because
cimetidine has an unpleasant taste.
Each rat was weighed daily and dosed by gavage. For
the first 15 weeks every rat received 10 ml/kg body wt
and from the 16th week 5 ml/kg body wt of the appro-
priate dose preparation. For the first 15 weeks cimetidine
solutions of 9.5, 3.78, and 1.5% (w/v) were used for
Groups 1, 2, and 3, respectively. These concentrations
were doubled from the 16th week onward. The method
of dosing described enabled us to achieve n accuracy
on each occasion of ± 2% of the stated dos,.
Observations during the study. All rats were in-
spected twice daily on weekdays for overt clinical signs
and given a thorough clinical examination once weekly.
On Saturdays, Sundays, and public holidays, one in-
spection was made. Moribund animals were killed on
the authority of one person (T.F.W.) and these and any
rats found dead were given a standard postmortem ex-
amination. Full histopathological examinations were
carried out, with the following exceptions: (1) 7 animals
which died in the first 4 weeks of the study, (2) 1 animal
from Group 3 which died on Week 24 and (3) 34 animals
from Groups 2 and 3 which comprised the 6-month kill
in these groups (see below). In case 1 no tissues were
taken. In cases 2 and 3 a full set of tissues was preserved
but only sections of the ovaries or testes, prostate or
uterus, seminal vesicles, and adrenals were examined.
In all three cases, detailed macroscopic observation at
necropsy failed to reveal the presence of any lesions
which indicated a need for microscopic assessment.
In a few instances, where autolysis was advanced, it
was not possible to obtain readable sections from all
tissues.
Body weights were recorded twice weekly during the
first 4 weeks and weekly thereafter. Food consumption
was measured after 4, 12, 24, 36, 48, 70, 82, 92, and
100 weeks in approximately 30 animals of each sex of
each group (15 from Batch A, 15 from Batch B).
Planned interim kills of rats in groups 1-4 were car-
ried out after 6 and 12 months (24 and 53 weeks) of
dosing. These animals had been specified before the test
commenced. An additional interim kill of animals from
all groups was carried out at 10 months (43 weeks) to
provide pathological material from control groups for
comparison with that of treated animals which had died
prematurely because of dosing accidents. All rats killed
at these times received standard post mortem and his-
topathological examinations. Details of the interim kills
are shown in Table 3. The terminal kill in all groups
was during Weeks 105 and 106.
Hematology and clinical chemistry. Blood samples
were taken from the tails of 10 males -and 10 females
of each group (5 from Batch A, 5 from Batch B) at the
following times after the start of the experiment: 7, 14,
27, 41, 53, 66, 83, and 103 weeks. The same rats were
bled on each occasion except that substitutes from the
same group and batch were used as replacements for
rats which died. All blood samples were examined for
hematological and clinical chemistry parameters (see
below) except that clinical chemistry measurements
were restricted to 5 males and 5 females from each
group (i.e., Batch A animals only) in the case of the
blood samples obtained at 7 weeks.
Hematological estimations comprised: hemoglobin


















COMPOSITION OF PRD DIET
Manufacturer's specification
Crude oil (%) 2.78 Choline chloride (mg) 200
Crude protein (%) 19.79 Folic acid (mg) 6
Crude fiber (%) 5.37 Nicotinic acid (mg) 20
Calcium (as Ca) (%) 0.72 Pantothenic acid (mg) 4
Phosphorus (as P) (%) 0.71 Amino acids added (%)
Salt (as NaC1) (%) 1.03 Arginine  1.25
Metabolizable Cystine 0.27
energy (kcal/kg) 2570 Glycine 0.97
Ash(%)* 4.8 Histidine 0.51
Moisture(%)* 10.3 Isoleucine 0.88
Trace elements Leucine 1.58
added (ppm) Lysine 1.07
Cobalt 0.4 Methionine 0.36
Copper 7 Phenylalanine 0.94
Iodine 1.3 Threonine 0.77
Iron (Fe) 30 Tryptophan 0.25
Magnesium 102 Tryosine 0.76
Manganese 25 Valine 1.04
Vitamins added to
each kg of diet
A (IU) 8000 Aflatoxin* Not detected
B 1 (mg) 2 (<0.02 ppm)
B2 (mg) 8 Nitrate (mg/kg) 3-15




* By independent analysis.
ics Ltd., Hertfordshire, U.K.); total erythrocyte count Coulter Counter Model ZF; platelet count by Coulter
(RBC), packed cell volume (PCV), mean corpuscular Thrombocounter and differential white cell count.
volume (MCV), and total leukocyte count (WBC) by	 Clinical biochemical estimation comprised: plasma
TABLE 2
ALLOCATION OF RATS FROM DIFFERENT BATCHES TO GROUPS
Group 5
Group 1	 Group 2	 Group 3	 Group 4	 (nondosed
(950 mg/kg)	 (378 mg/kg)	 (150 mg/kg) (distilled water)	 controls)
Batch Males Females Males Females Males Females Males 	 Females	 Males Females
A (September 1974) 45 44° 30 30 30 30 40 40 37 30
B (October 1974) 45 45 30 30 30 30 39° 40 20 28
C (February 1975)b 0 0 0 0 0 0 0 0 50 50
D (June 1975)b 10 10 10 10 5 5 5 5 0 0
Totals 100 99 70 70 65 65 84 85 107 108
° One rat in Group 1 lost at Week 63; one rat in Group 4 lost at Week 105.
b Batches C and D, which were added later to the study and ran the full 106 weeks, were examined for incidence
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glucose, plasma glutamate pyruvate transaminase,
plasma glutamate oxaloacetic transaminase (only from
week 27 onward), and plasma alkaline phosphatase, all
by an Abbott ABA 100 Bichromatic Analyser (Abbott
Diagnostics, Kent, U.K.).
At the 12-month interim kill and at the terminal kill
(Week 105-106), blood samples were taken from both
the tail and from the inferior vena cava of all rats, and
the following additional clinical chemistry parameters
were measured: blood urea nitrogen (BUN), bilirubin,
and total protein by Abbott ABA 100 Bichromatic An-
alyser; plasma sodium and potassium by IL 343 Pho-
tometer (Instrumentation Laboratories Ltd., Warring-
ton, U.K.); chloride by an EEL 920 chloride meter (V.A.
Howe & Co. Ltd., London, U.K.); plasma albumin and
plasma acid phosphatase (male rats only) by Technicon
Instruments Co. Ltd. (Hants., U.K.); cholesterol by
Eskalab Alpha (Smith Kline Instruments Co. Ltd.,
Hertfordshire, U.K.). Full hematological and clinical
chemistry determinations also were made for all rats
killed before Week 105 due to ill health.
Urinalysis. Four-hour samples of urine were collected
before the test began and after 6, 13, 26, 39, 52, 65, 82,
and 103 weeks of dosing from the same rats as were
used for the hematological investigations. The following
parameters were measured: volume; specific gravity by
Goldberg refractometer (American Optical Co.); pres-
ence of glucose by Clinistix (Ames) and the level by
Abbott ABA autoanalyser, if required, and protein level
by Chemlab autoanalyser (Chemlab Instrument Co.
Ltd., London, U.K.). The spun sediment was examined
microscopically and urine cell counts were made.
Ophthalmoscopy. The eyes of 10 male and 10 female
rats from each group were examined by direct ophthal-
moscopy after mydriasis with 1% Tropicamide (BP) at
the following times after the start of the study: Batch
A at 15, 27, and 53 weeks; Batch B at 11, 23, and 49
weeks. At the end of the study the eyes of all surviving
rats were examined.
Sacrifice and postmortem examination. Rats were
killed by ether overdose and bled via the posterior vena
cava. Each animal was subjected to a thorough exam-
ination postmortem. The heart, liver, gonads, kidneys,
adrenals, seminal vesicles, prostate or uterus, and brain
were weighed. Samples of these organs, and of the
tongue, eye, salivary gland, cervical lymph node, thy-
roids, lungs, thymus, aorta, sternal bone and marrow,
bladder, stomach, duodenum, small and large intestines,
pancreas, spleen, mesenteric lymph node, pituitary, skin,
mammary gland, nerve, voluntary muscle, and any tis-
sue of grossly abnormal appearance were fixed in formal
sublimate solution (1 part saturated mercuric chloride:
4 parts 10% formalin). Sections of these tissues stained
with hematoxylin and eosin were examined microscop-
ically.
Statistical methods. In the case of body weights, food
consumption, hematology and clinical chemistry param-
eters, and organ weights, group mean values were corn-
pared when considered appropriate by pooled Student's
t tests. Statistical analysis of tumor incidence data was
carried out according to the methods recommended by
Peto (1974) and Peto et al. (1980). Tumors were clas-
sified as either incidental (discovered at postmortem or
histopathological examination of an animal which died
or was killed for another reason) or nonincidental (caus-
ing death or contributing to the cause of death).
RESULTS
Clinical Observations (Batches A and B
Only)
Excessive salivation was commonly ob-
served immediately after dosing with cime-
tidine in high dose rats (Group 1) and, oc-
casionally, in medium dose rats (Group 2).
Perineal soiling was also commonly seen in
Group 1 rats, but in no other group. No un-
usual clinical signs were associated with
treatment with cimetidine.
Food Consumption (Batches A and B Only)
Food consumption was similar in all
groups. Mean daily food consumption for
males and females decreased from 29 g and
22 g, respectively, in the early weeks of the
study to 22 g and 18 g, respectively, in the
latter weeks.
Body Weights (All Batches)
Body weight gain was not affected by
treatment with cimetidine (Figs. 1 and 2).
Survival (All Batches)
Many animals in the cimetidine-treated
groups died or were killed because of dys-
pnoea, presumed to be due to reflux of the
esophageally administered dosing solution
into the trachea or, in a few instances, direct
administration into the trachea. The mode
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FIG. 1. Body weights of male rats. Each point represents the mean for survivors at that week.
of death (e.g., frothing at the mouth) and
pathological changes in the lungs were con-
sistent with this presumption.
As most deaths attributable to dosing ac-
cidents occurred at the higher dose levels:
64/199 in Group 1 (950 mg/kg), 47/140 in
Group 2 (378 mg/kg), 18/130 in Group 3
(150 mg/kg), and only 2/169 in Group 4
(distilled water controls), a subsidiary ex-
periment was carried out to investigate the
toxicity of cimetidine solutions when delib-
erately administered by the intratracheal
route.
Male rats weighing 460-600 g were lightly
anesthetized with ether and dosed once by
the intratracheal route. Ten rats received 1.0
ml/kg distilled water, 10 received 1.0 ml/kg
of 19% (w/v) cimetidine solution, taken
from the Group 1 dosing solution. The ci-
metidine dosage was 190 mg/kg. All 10 rats
receiving cimetidine suffered severe, pro-
longed dypsnoea and five died within 1 hr
of treatment. The rats receiving distilled
water suffered only slight, brief dypsnoea,
and none died. This confirmed that cimeti-
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FIG. 2. Body weights of female rats. Each point represents the mean for survivors at that week.
was more acutely toxic than water admin-
istered by the same route or cimetidine ad-
ministered intragastrically.
After correction for deaths attributable to
dosing accidents, survival rates were not sig-
nificantly different in treated and control
groups (Figs. 3 and 4). Excluding dosing
accidents, the death rate in all groups was
relatively low until the last 6 months of the
study, when it rose in all groups in a similar
fashion. Within any group, the survival rates
varied among batches (Table 3), but no con-
sistent difference was seen in the survival
rate of one batch compared with the other.
Hematology and Clinical Chemistry
(Batches A and B)
Despite wide variations in hematological
values, both within and between groups,
comparison of mean group values at no time
revealed any changes which could be attrib-
uted to treatment with cimetidine. Trans-
aminase levels were higher in Group 1 males
(950 mg/kg) than in control males during
the second year of the study (Tables 4 and
5) 1 but these differences were only statisti-
cally significant at Weeks 66 and 103. No
such changes were seen in transaminase lev-
els among females. No other treatment-re-
lated changes were seen for any other clin-
ical biochemical parameter.
See NAPS document No. 03855 for 25 pages of
supplementary material. Order from ASIS/NAPS c/o
Microfiche Publications, P.O. Box 3513, Grand Central
Station, New York, N.Y. 10017. Remit in advance in
U.S. funds only for each NAPS Accession Number.
Institutions may use purchase orders when ordering;
however, there is a billing charge for this service. Make
checks payable to Microfiche Publications. Photocopies
are $5.00. Microfiche are $3.00. Outside of the U.S. and





























127CIMETIDINE TOXICITY IN RATS
50
0    
1	 10	 20	 30 40	 50
Week
60	 70	 80	 90	 100	 110
FIG. 3. Percentage survival of male rats up to Week 104. Rats whose deaths are attributed to dosing
accidents have been excluded.
Urinalysis (Batches A and B)
No treatment-related effects were ob-
served during the study.
Ophthalmoscopy (Batches A and B)
No abnormalities were seen which were
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FIG. 4. Percentage survival of female rats up to Week 104. rats whose deaths are attributed to dosing
accidents have been excluded.
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Postmortem Observations (All Batches)
Postmortem evidence of lung dosing—
patchy, hemorrhagic lungs, and the presence
of fluid in the trachea—was commonly seen
in rats from the two higher dose groups
which died or were killed in extremis, es-
pecially during the first year of the study.
Otherwise no gross abnormalities were seen
that are not commonly encountered in aged
rats and there was no excess of particular
abnormalities in treated as compared with
control groups.
Organ Weights (Batches A and B)
Among the animals killed at the end of the
study, a significant increase was seen in the
mean liver weight in Group 1 females (950
mg/kg) compared with either Group 4 (dis-
tilled water controls) or Group 5 females
(nondosed controls) (Table 6). Among males,
the mean liver weights in Group 1 were raised
compared with those in the control groups
(Table 7), but not significantly so.
During the second year of the study, sem-
inal vesicles and prostates were noted to be
smaller than usual in 21/55 male rats in
Group 1, 5/30 in Group 2, 2/31 in Group
3, 2/54 in Group 4,and 0/49 in Group 5.
Among rats killed at the end of the study,
the mean group prostate and seminal vesicle
weights were significantly lower in all three
dose groups than those of the two control
groups (Table 7). The decrease in weights
was clearly dose related. Testis weights were
significantly lower in the top dose group
(Group 1) compared with the nondosed con-
trols (Group 5), but not compared with the
distilled water controls (Group 4) (Table 7).
Apart from the findings listed above, no sig-
nificant differences were seen in the weights
of any other organs and no further post-
mortem changes were seen which were con-
sidered to be associated with cimetidine
treatment.
Histopathological Findings
(A) Nonneoplastic pathology (Batches A
and B only). The findings other than those
for neoplasms are summarized in Table 81
for decedents and for animals killed at 6 and
12 months and in Table 9' for animals killed
terminally.
In general the findings were unremarka-
ble. In the glandular stomach, a few animals
of both sexes in all groups exhibited focal
distention of gastric glands, edema, or in-
flammation. The incidence was not related
to dose. No treatment-related changes were
observed in the forestomach, pancreas, or
spleen.
In the liver, top dose males exhibited
higher incidences of centrilobular vacuola-
tion of hepatocytes, probably because of
fatty degeneration, of centrilobular hepato-
cellular enlargement, minimal to moderate
bile duct hyperplasia, and hepatocyte necro-
sis. A slightly higher incidence of centrilob-
ular hepatocellular enlargement was seen in
top dose females killed terminally. There
was no treatment-related effect on these pa-
rameters nor on any other parameter for
liver pathology in animals of either sex ex-
posed to the middle or low dose levels of the
drug.
As expected in rats aged over 2 years,
animals in all four groups killed terminally
exhibited a high incidence of involution of
the thymus, manifest as cortical hypoplasia.
There was no evidence that the treatment
influenced the incidence or severity of this
change or any other feature of thymic pa-
thology. Similarly no treatment-related ef-
fects were observed in the mesenteric lymph
node or bone marrow.
In the endocrine system, an approximately
equally low incidence of hypertrophy of
parathyroid gland tissue was seen in all
groups. The pathological findings in the thy-
roid included the presence of branchial cleft
remnants, cysts, and distended follicles. Only
two rats in the whole study exhibited hy-
perplastic lesions (one Group 1 female de-
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cedent had focal parafollicular hyperplasia
and one Group 4 male decedent had focal
follicular cell hyperplasia). The lack of any
obvious treatment-related increase in hyper-
plastic lesions of the thyroid suggests that
the slightly higher incidence of benign thy-
roid tumors in Groups 1 and 2 animals (see
next section) was a chance finding. A variety
of nonspecific changes was observed in the
adrenals of all groups, but taking the find-
ings for decedents and animals killed ter-
minally together, there is clearly no evidence
of any treatment-related effect. Cystic
changes, hypertrophy, and chromophobe cell
hyperplasia of the pituitary gland were no
more frequent in treated groups than in the
controls.
The kidneys of rats of both sexes in all
groups showed changes indicative of slight
to marked chronic tubular nephrosis, a con-
dition which occurs very commonly in un-
treated aged rats of many strains. The fea-
tures of the condition include round cell
infiltration, the presence of eosinophilic tu-
bular casts, multiple foci of tubular hyper-
plasia, and, in a few instances, areas of in-
terstitial fibrosis. The data displayed in
Tables 8 and 9 indicate that treatment was
not associated with any adverse effect on the
incidence or severity of these or any other
renal changes.
The lungs of most rats exhibited minimal
to slight pneumonitis and deposits of round
cells around main airways. These changes
are a more or less universal finding in aged
rats. The fact that they were rarely more
than slight in severity reflects the fact that
the experiments were conducted under care-
fully maintained specified pathogen-free
conditions. In animals killed terminally, it
is clear from Table 9 that treatment was not
associated with any increased incidence or
severity of the condition. As has been made
clear above, there were several early deaths
in Groups 1, 2, and 3 because of the entry
of drug solution into the lungs during ga-
vage. A dose-related increased incidence of
pulmonary congestion and edema attribut-
able to this is evident in the data for dece-
dents summarized in Table 8. It is notewor-
thy that there is no treatment-related increase
in pulmonary congestion in rats killed ter-
minally (see Table 9). A variety of other
pulmonary lesions was recorded but in no
case was the incidence associated with treat-
ment.
No treatment-related changes were seen
in the heart. No pathology changes what-
soever were seen in the brain in any group.
In the eye, focal, extensive, or complete ret-
inal atrophy was seen in 5/89 Group 1 males
(4/59 decedents and 1/30 terminal kill) and
14/87 Group 1 females (5/56 decedents and
9/31 terminal kill) compared with 8/79
Group 4 males and 15/78 Group 4 females.
These figures are consistent with no treat-
ment-related effects on this parameter. In
our opinion, the fact that in rats killed ter-
minally the retinal atrophy was graded as
complete in 6/31 Group 1 females compared
with only 2/29 Group 4 females is a chance
finding.
There was no evidence of any effect of
treatment on voluntary muscle, skin, the
ovaries, or the uterus. Mammary gland hy-
perplasia and galactocoele formation were
less frequent in treated than control females.
In males killed terminally (Table 9), there
was evidence of the known, weak antiandro-
genic effects of cimetidine (Leslie and
Walker, 1977) in terms of a treatment-re-
lated increase in atrophy of the seminiferous
tubules of the testis (Group 1, 16/30 rats
affected; Group 2, 4/13; Group 3, 6/21;
Group 4, 6/30; Group 5, 4/27) and atrophy
of the seminal vesicles (Group 1, 17/30;
Group 2, 3/13; Group 3, 5/21; Group 4, 1/
30; Group 5, 0/27), prostate (Group 1, 17/
29; Group 2, 2/13; Group 3, 4/21; Group
4, 1/30; Group 5, 0/27) and epididymides
(Group 1, 9/27; Group 2, 1/13; Group 3,
0/18; Group 4, 1/30; Group 5, 0/27). Al-
though an increased incidence of Leydig-cell
tumors was seen in cimetidine-treated rats
(see next section) there was no parallel in-
crease in the incidence of Leydig-cell hy-
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perplasia (Group 1, 3/30; Group 2, 1/13;
Group 3, 2/21; Group 4, 1/30; Group 5,
3/27).
(B) Overall tumor incidence (all Batches).
No neoplasms were seen in rats sacrificed
at 6 months. Among 16 rats from Group 5
(nondosed controls) sacrificed at the 10-
month interim kill two tumors were seen: an
adenoma of the lung and a chromophobe
adenoma of the pituitary. No tumors were
seen among 19 rats from Groups 1 to 4 killed
at this time.
Among 65 rats from Groups 1 to 4 sac-
rificed at the 12-month interim kill, eight
tumors were seen: a mesothelioma in a
Group 1 male; a papillary carcinoma of the
mammary gland in a Group 4 female;
chromophobe adenomas of the pituitary in
a Group 1 male, a Group 3 female, and a
Group 4 female; a hemangioma of the ax-
illary lymph node in a Group 3 male; a
phaeochromocytoma in a Group 3 female;
and a mammary fibroadenoma in another
Group 3 female.
No neoplasms were seen in any rat dying
before Week 16. The results for all decedents
from Week 16 onward are listed in Table
10. 1 Survival differences among groups need
to be taken into account in the interpretation
of the data depicted in this table. There was
a considerably lower overall tumor rate, both
for male and female rats, in the cimetidine-
treated groups than in the control groups,
as would be expected in view of the higher
number of premature deaths in the cimeti-
dine-treated groups.
The incidence of tumors among rats killed
terminally is shown in Table 11. 1 Although
the mean number of neoplasms per survivor
was lower both in the males (0.62) and the
females (0.48) of Group 5 (nondosed con-
trols) than in any of the four dosed groups,
including the distilled water controls (range,
0.88-1.29 in males, 0.79-1.03 in females),
tumor incidence for each sex was similar
among the three cimetidine-treated groups
and the distilled water controls. A slightly
higher overall incidence of tumors in male
survivors in the cimetidine-treated groups
compared with Group 4 is explained by the
higher incidence of Leydig-cell tumors
among these animals (Table 12).
(C) Specific tumor types. A low inci-
dence of pancreatic tumors in treated groups
but not in controls (Islet-cell tumors in two
males of Group 1 killed at 104 and 106
weeks, respectively, exocrine adenomas in
two males of Group 1 killed at 101 and 106
weeks, respectively, and a mixed endocrine/
exocrine adenoma in a female of Group 3
killed at 103 weeks) is considered to have
been a chance finding (see Discussion).
The data for four types of tumor—pitui-
tary tumors in both sexes, mammary tumors
in females, Leydig-cell tumors in males, and
follicular neoplasms of the thyroid gland—
were combined, respectively, for decedents
and terminal kill animals and analyzed sta-
tistically.
Leydig-cell tumors.The proportions of
rats with Leydig-cell tumors of the testis are
shown in Table 12. The data were analyzed
using the method for incidental tumors, with
the modification that the x2 statistic contains
a contribution from rats without tumors.
A significantly higher incidence of Ley-
dig-cell tumors was seen in the combined
cimetidine-treated groups compared with
the combined control groups, both for rats
killed or dying at any time during the study
(Weeks 1-106) and for rats killed during
Weeks 105 and 106. The incidence of Ley-
dig-cell tumors in the combined cimetidine-
treated groups was not significantly different
from that in the combined control groups
among rats dying during Weeks 79 and 104.
The difference in tumor incidence was there-
fore confined to animals killed during Weeks
105 and 106. Within the cimetidine-treated
groups there was no dose-related trend in
incidence of Leydig-cell tumors (Table 12).
Tumors of the pituitary gland. The in-
cidence of pituitary tumors among survivors
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TABLE 12
















Total° 23/98h 14/68' 15/65d 13/84 22/107
Percentage incidence
of tumors 23.5 20.6 23.1 15.5 20.6
0-26 Weeks 0/18 0/16 0/13 0/11 0/0
27-54 Weeks 0/21 0/18 0/18 0/15 0/10
55-78 Weeks 0/9 4/10 0/2 0/2 2/8
79-104 Weeks' 6/16 4/10 3/8 6/22 9/31
105-106 Weeksf 17/34g 6/14h 12/24' 7/34 11/58
Note. Number of rats with a tumor/number of rats killed or dying with adequate pathological examination.
a Significant difference between combined cimetidine-treated groups and combined control groups, x 2(1) = 11.79,
p < 0.001.
b Significantly different from combined control groups, x 2(1) = 6.33, p < 0.025.
Not significantly different from combined control groups, x 2(1) = 3.40, p > 0.05.
d Significantly different from combined control groups, x 2(1) = 5.81, p < 0.025.
e No significant difference between combined cimetidine-treated groups and combined control groups, x 2(1) =
0.54, p > 0.05.
f Significant difference between combined cimetidine-treated groups and combined control groups, x 2(1) = 14.27,
p < 0.001.
g Significantly different from combined control groups, x2(1) = 10.01, p < 0.005.
h Not significantly different from combined control groups, x2(1) = 2.55, p > 0.1.
Significantly different from combined control groups, x 2(1) = 7.67, p < 0.01.
was lower in the females of Group 1 (high
dose, 7/34) and Group 5 (nondosed, 12/71)
than in other groups (Group 2, 8/18; Group
3, 9/26; Group 4, 12/32) (Table 11). How-
ever, none of the differences between the in-
dividual groups was statistically significant
nor was the difference between the combined
cimetidine-treated groups and the combined
control groups significant.
For both male and female rats, the pat-
terns of incidence for incidental and nonin-
cidental tumors (see Statistical Methods for
definition) were scrutinized but no treat-
ment-related effect was seen.
Tumors of the thyroid gland. A total of
18 rats in the study were found to have thy-
roid tumors at necropsy. Six cases of para-
follicular adenoma appeared to be distrib-
uted randomly between treated and control
groups. One nondosed control male was
killed because of a large follicular cell car-
cinoma during the 103rd week of the study
and a nondosed female was found to have
a follicular cell carcinoma when it was killed
at the end of the study. By contrast, no rat
in the three cimetidine-treated groups de-
veloped a malignant tumor of the thyroid
gland. However, the number of rats with
benign or malignant tumors of follicular cell
origin was slightly higher in Groups 1 and
2 than in other groups (Group 1, 4/98 males
and 1/96 females; Group 2, 1/59 males and
2/62 females; Group 3, 0/57 males and 1/
55 females; Group 4, 1/84 males and 0/85
females; Group 5, 1/107 males and 1/108
females). Only two of the benign neoplasms,
both incidental, occurred in decedents (a
Group 1 male killed in Week 82 and a Group
2 male dying in Week 73). All other follic-
ular adenomas were observed in rats killed
at the end of the study. For this reason, and
as survival rates between Weeks 55 and 106
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did not vary significantly among groups, a
statistical analysis was performed on the
proportions of rats with follicular cell tumors
killed or dying during the second year of the
study. Ignoring the nature of the tumors, i.e.,
whether they were benign or malignant, the
incidence in the pooled cimetidine-treated
groups, if males and females are combined,
is greater than in the pooled control groups,
and in Group 1 the incidence in males alone
is significantly higher than in the other group
males (p < 0.05, exact test). However, a car-
cinoma is clearly a more serious and ad-
vanced lesion than an adenoma. For this rea-
son we do not believe that the slight excess
of benign tumors in Group 1 has any bio-
logical significance.
Tumors of the mammary gland. Analyses
were carried out separately for all rats with
histopathologically confirmed mammary tu-
mors, and for rats with malignant tumors
only, using the method for nonincidental tu-
mors and taking the week that the tumor
was first observed as the first occurrence.
Table 13 shows the number of tumors ob-
served (0) and the number expected (E)
under the null hypothesis that tumor rate is
independent of treatment.
For both malignant mammary tumors and
for all mammary tumors, incidence rates
were significantly higher in the distilled
water group than in the other groups. Fur-
ther analysis of the data for all mammary
tumors showed that the excess in the distilled
water group was not apparent before Week
83 nor after Week 103 but was very marked
between those weeks (0 + 02 + 03 + 05
= 8, E i + E2 E3 = 19.67; 04 = 16, E4
= 4.33; x2(1) = 38.3, p < 0.001). During this
period, of 49 tumorless survivors in Group
4, 16 (32.7%) developed a tumor by Week
103. In the other four groups combined the
proportion was only 8 out of 185 (4.3%).
There were no significant differences in
tumor rates between the three cimetidine-
dosed groups and the nondosed controls and,
hence, no evidence that cimetidine affected
the risk of development of mammary tumors.
DISCUSSION
Previous studies with cimetidine had in-
dicated that it was a powerful inhibitor of
gastric acid secretion (Brimblecombe et al,
1975) and that weak antiandrogenic effects
were to be expected in response to treatment
at each of the dose levels chosen (Leslie and
Walker, 1977), the mechanism possibly being
that cimetidine, itself a weak androgen,
blocks the cytoplasmic receptor sites for di-
TABLE 13






Group 1 (950 mg/kg) 13 13.84 3 4.78
Group 2 (378 mg/kg) 3 7.43 2 2.41
Group 3 (150 mg/kg) 10 10.49 5 3.41
Group 4 (distilled water) 23 12.77' 9 4.624
Group 5 (nondosed controls) 22 26.47 5 8.78
a Significant difference between all five groups, x2 = 11.67, p < 0.05.
No significant difference between groups.
Significant difference between distilled-water controls and other four groups, x2 = 10.00, p < 0.01.
Significant difference between distilled-water controls and other four groups, X2 = 5.14, p < 0.05.
CIMETIDINE TOXICITY IN RATS	 135
hydrotestosterone (Winters et al., 1979).2
Also, Crean et al. (1978) reported evidence
of hypertrophy of antral and fundal gastric
mucosa in rats. It was, therefore, of partic-
ular interest in the present study to look for
changes in the gastrointestinal tract, gonads,
and secondary sex organs. Administration
by gavage, chosen because of the unpleasant
taste of cimetidine, presented problems be-
cause aqueous solutions of cimetidine are
poorly tolerated if they enter the lungs. A
few animals were lost because of accidental
instillation into the trachea but more died
prematurely because of seepage of cimeti-
dine solution from the esophagus into the
lungs via the larynx during or immediately
after its introduction into the lower esoph-
agus or stomach. Apart from these prema-
ture deaths, cimetidine treatment was as-
sociated with few effects and with none
which adversely affected survival.
No significant adverse effects were ob-
served on food consumption, body weight,
clinical signs, behavior, ophthalmoscopy, or
in biochemical, hematological, or urinalysis
parameters in response to cimetidine. In-
creases in mean liver weight and occasional
elevations of transaminase levels in rats re-
ceiving cimetidine 950 mg/kg/day were as-
sociated with a higher incidence of centri-
lobular hepatocellular vacuolation and
enlargement, bile duct hyperplasia and
hepatocyte necrosis in males and, in females,
a slightly higher incidence of centrilobular
hepatocellular enlargement. The latter
change fell into Squire and Levitt's (1975)
category "foci or areas of cellular altera-
tion."
With the possible exceptions of mammary
tumor incidence in females, Leydig-cell tu-
mors in males, and follicular tumors of the
thyroid gland, no significant treatment-re-
lated effects on tumor incidence were ob-
served after survival differences had been
allowed for. It is considered that the occur-
rence of two Islet-cell adenomas and two
cases of exocrine adenoma of the pancreas
in high-dose males, and one case of mixed
Islet-cell and exocrine adenoma in a low-
dose female, despite the absence of tumors
of either of these kinds in either control
group, was a chance finding. Tumors of both
these kinds are of common occurrence in lab-
oratory rats, but the factors which affect the
incidence of the one do not as a rule influ-
ence that of the other.
A significantly (p < 0.001) higher inci-
dence of mammary tumors was encountered
in females of the distilled water control
group which died between Weeks 83 and 103
but not before the 83rd week and not after
the 103rd week. The observation is consid-
ered to be spurious since there was no par-
allel excess incidence in untreated females
during this period and no dose-related de-
ficiency of mammary tumors in females in
the cimetidine-treated groups. Follicular ad-
enomas of the thyroid gland were encoun-
tered more frequently in high-dose males
(4/98) than in any other group. This was
not considered to indicate an effect of treat-
ment since all four tumors were benign,
whereas one untreated control male devel-
oped a malignant tumor of follicular origin,
and there was no pattern suggestive of treat-
ment in females. In any study of the present
kind where large numbers of comparisons
are made for tumors of different types, sta-
tistically significant differences are bound to
appear by chance. Where excess incidences
affect low-dose or control groups, it is the
usual practice to accept them as spurious as
we have done with the excess of mammary
tumors in the distilled-water control group
(see above).
Cimetidine (475 mg/kg b.i.d.) has been
shown to decrease the growth rates of the
prostate and seminal vesicles of castrated
adult rats treated exogenously with testos-
terone when both were given over a 7-day
period. 3 It was not surprising, therefore, in
2 H. Saunders, and P. Sivelle, personal communica-
tions.	 3 P. Sivelle, personal communication.
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the present study, to find that the group
mean prostate and seminal vesicle weights
in rats killed terminally were significantly
lower in all treated groups than in the con-
trols. The known, weak antiandrogenic ef-
fect of cimetidine (Leslie and Walker, 1977)
was also expressed as a treatment-related
increase in atrophy of the seminiferous tu-
bules and atrophy of the seminal vesicles,
prostate, and epididymides in rats killed ter-
minally. In spite of its weak antiandrogenic
activity, cimetidine has no effect on the mat-
ing performance or fertility of male rats
treated for at least 70 days before mating
at any of the three dose levels in the present
study. No effects were seen on either the
morphology or reproductive capability of the
male offspring of female rats treated with
cimetidine up to 950 mg/kg/day during
pregnancy and lactation (Leslie and Walker,
1977).
There is no clear way of distinguishing
between Leydig-cell hyperplasia and neopla-
sia other than by size of lesion. In the present
study, we regarded foci of hyperplastic Ley-
dig cells of 1 mm diameter or more as neo-
plasms. Irrespective of their size such lesions
are nonfatal. In other words, their presence
is normally first detected in animals that
have died from other causes. Although ex-
posure to high doses of cimetidine was, over-
all, associated with an increased incidence
of Leydig-cell tumors so defined, the results
are somewhat puzzling in that the excess of
tumors was not associated with any excess
of lesions classified as Leydig-cell hyperpla-
sia, was confined to animals which survived
to week 105 or 106 of the study and showed
no dose-related trend. Since 15-20% of con-
trol animals (Groups 4 and 5) killed at the
end of the experiment exhibited testicular
atrophy and 20% had Leydig-cell tumors, it
is questionable whether rats of the strain
used were suitable for predicting the effect
of antiandrogenic activity in the testis of
other species, including man.
When Leydig-cell tumors are excluded,
the pattern of mean numbers of neoplasms
per survivor was consistent with there being
no effect of cimetidine on the incidence of
any kind of neoplasm, benign or malignant.
The size of the difference in overall tumor
incidence between the dosed and nondosed
controls illustrates once again the extent to
which nonspecific factors, such as dosing
with distilled water by gavage, may influ-
ence tumor incidence (Riley, 1975).
Although the mean pharmacological ac-
tion of cimetidine is to reduce the secretion
of acid in the stomach, no evidence of any
pathological change attributable to treat-
ment was observed either in the stomach or
elsewhere in the gastrointestinal tract in the
present study, despite the hypertrophy of
antral and fundal mucosa reported earlier
(Crean et al., 1978).
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